AzTrials
AzTrials

Stage II Grade B PeriodontitisNCT07801417

Clinical & Biochemical Evaluation of Antioxidant Vs. Chlorhexidine as an Adjunctive to Non-Surgical Treatment of Stage II-grade B Periodontitis

A study testing Perioscience Gel, High Cure Chlorhexidine Gel and High Cure Chlorhexidine Gel + Perioscience Gel in people with Stage II Grade B Periodontitis, run by Al-Azhar University at 1 site in Egypt.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This randomized clinical trial aims to evaluate and compare the clinical and biochemical effects of an antioxidant agent and chlorhexidine when used as adjuncts to non-surgical periodontal therapy in patients with Stage II Grade B periodontitis. Read more about this study

Who is it for?
Ages 25 to 40 months
Conditions the study is for
Stage II Grade B Periodontitis
What is being tested?
Perioscience Gel, High Cure Chlorhexidine Gel and High Cure Chlorhexidine Gel + Perioscience Gel
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
36 participants
Where
1 siteEgypt
Study dates
1 Dec 2025to 1 Jul 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 25 to 40 months
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • 1- Patients diagnosed as having stage II periodontitis (22) 2- Clinical attachment loss ranged from 3-4mm 3- Radiographic bone loss ranged from 15% to 30%, mostly horizontal 4- Male or female aged from 25 - 40 years old

Who cannot join

  • 1- Smoking patient 2- Pregnancy and breastfeeding patients. 3- Patients with systemic conditions which could affect the outcome of periodontal therapy.
  • 4- Previous periodontal therapy in last 6 month.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Alazhar University

    Cairo, Cairo Governorate, 11651

Other trials in Egypt

About this study

Official title: Clinical & Biochemical Evaluation of Antioxidant Vs. Chlorhexidine as an Adjunctive to Non-Surgical Treatment of Stage II-grade B Periodontitis.

This randomized clinical trial aims to evaluate and compare the clinical and biochemical effects of an antioxidant agent and chlorhexidine when used as adjuncts to non-surgical periodontal therapy in patients with Stage II Grade B periodontitis. Eligible participants will receive scaling and root planing (SRP) and will be randomly assigned to either the antioxidant or chlorhexidine treatment group. Clinical periodontal parameters, including plaque index, gingival index, probing depth, and clinical attachment level, will be assessed at baseline and follow-up visits. Biochemical analysis of inflammatory markers, including tumor necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1), will be performed to evaluate the inflammatory response to treatment. The study aims to determine whether antioxidant therapy provides comparable or superior benefits to chlorhexidine as an adjunct to non-surgical periodontal treatment.

Being tested
Perioscience Gel, High Cure Chlorhexidine Gel, High Cure Chlorhexidine Gel + Perioscience Gel, Scaling and Root Planing (SRP)

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Perioscience GelDrug

    Local application of Perioscience antioxidant gel into periodontal pockets following scaling and root planing (SRP).

  • High Cure Chlorhexidine GelDrug

    Local application of High Cure chlorhexidine gel into periodontal pockets following scaling and root planing (SRP).

  • High Cure Chlorhexidine Gel + Perioscience GelDrug

    Local application of both High Cure chlorhexidine gel and Perioscience gel into periodontal pockets following scaling and root planing (SRP).

  • Scaling and Root Planing (SRP)Procedure or surgery

    Conventional full-mouth scaling and root planing performed using ultrasonic and hand instruments.

Study groups in NCT07801417
Study groupRoleWhat they receive
Perioscience Gel + SRPExperimentalParticipants receive scaling and root planing (SRP) followed by local application of antioxidant gel.
Receives: Drug: Perioscience Gel
Chlorhexidine Gel + SRPExperimentalParticipants receive scaling and root planing (SRP) followed by local application of chlorhexidine gel.
Receives: Drug: High Cure Chlorhexidine Gel
Antioxidant Gel + Chlorhexidine Gel + SRPExperimentalParticipants receive scaling and root planing (SRP) followed by local application of both antioxidant gel and chlorhexidine gel.
Receives: Drug: High Cure Chlorhexidine Gel + Perioscience Gel
SRP AloneActive comparatorParticipants receive scaling and root planing (SRP) only, without adjunctive gel application.
Receives: Procedure: Scaling and Root Planing (SRP)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Gingival Crevicular Fluid (GCF) Level of Interleukin-1 (IL-1)

    Changes in the concentration of Interleukin-1 (IL-1) in gingival crevicular fluid (GCF) will be assessed before and after the intervention using an enzyme-linked immunosorbent assay (ELISA) with unit of measurement pg/mL .

    Measured: Baseline to 6 months after treatment

  2. Gingival Crevicular Fluid (GCF) Level of Tumor Necrosis Factor-alpha (TNF-α)

    Changes in the concentration of Tumor Necrosis Factor-alpha (TNF-α) in gingival crevicular fluid (GCF) will be assessed before and after the intervention using an enzyme-linked immunosorbent assay (ELISA) with unit of measurement pg/mL .

    Measured: Baseline and 6 months after treatment

Secondary outcomes (4)
  1. Probing Depth (PD)

    Probing depth will be measured in millimeters using a periodontal probe at the selected periodontal sites.

    Measured: Baseline to 6 months after treatment.

  2. Gingival Index (GI)

    Gingival status will be assessed using the Gingival Index, scored (0 - 3) at the selected periodontal sites.

    Measured: baseline to 6 months after treatment

  3. Clinical Attachment Level (CAL)

    Clinical attachment level will be measured in millimeters using a periodontal probe at the selected periodontal sites.

    Measured: baseline to 6 month after treatment

  4. Plaque Index (PI)

    Dental plaque accumulation will be assessed using the Plaque Index, scored (0 - 3) at the selected periodontal sites.

    Measured: baseline to 6 month after treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Sep 2026
  2. Study start1 Dec 2025
  3. Primary completion1 Dec 2025
  4. Study completion1 Jul 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
36 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07801417
Sponsor's protocol ID
OMPDR-105-1w
Status last verified
Aug 2026
First submitted
26 Jun 2026
Last updated
3 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Perioscience Gel, High Cure Chlorhexidine Gel and High Cure Chlorhexidine Gel + Perioscience Gel in people with Stage II Grade B Periodontitis, run by Al-Azhar University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 3 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Gingival Crevicular Fluid (GCF) Level of Interleukin-1 (IL-1) (time frame: Baseline to 6 months after treatment). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in